0
POPSPfizer and Medivation Enter Deal On Alzheimer's Pfizer will partner with the small biotech firm on dimebon, an experimental drug for Alzheimer's and Huntington's disease. But there is debate among investors over whether early, promising results from studies in Russia will translate into effectiveness in larger clinical trials. Pfizer will pay $225 up front and $500 million in bio-bucks. It will pay for 60% of development costs and get 60% of profits.
0
POPSNew Treatment for Alzheimer’s Disease? In July 2003 some treatments for Alzheimer's treatments were brought to attention at the Alzheimer’s Association International Conference on Alzheimer’s disease (ICAD 2008). Some of these treatments showed great potential.
9
POPS‘Robot Suit’ Helps Paralyzed People Walk ReWalk is expected to be sold in 2010 with a price tag of about $20,000. It is currently in clinical trials in Tel Aviv’s Sheba Medical Centre and more trials are expected to take place at the Moss Rehabilitation Research Institute in Pennsylvania.
22
POPSDrug tries to offset 10,000 years of evolution Gene therapies, expected some time between 2015 and 2020, promise to correct this genetic problem caused by nature, but many obese people do not want to wait. They are hoping that Nastech’s new nasal spray can provide a solution now. Within 20 to 35 minutes after taking a whiff, this new drug moves quickly through the nasal lining and into the bloodstream, sending a message to the brain that our tummy is full. So far the drug has had no negative side effects. PYY is undergoing clinical trials now, and is expected to be in drug stores by 2009 or 2010. Obesity is the 2nd leading cause of preventable death in America, so this drug offers a great chance for more people to improve their health and get ready to enjoy our “magical future”.
5
POPSOxygen may ease headache and migraine Breathing oxygen as opposed to what? I wonder if it has anything to do with the air being clean. Perhaps fresh air would have a similar effect. Fresh air is getting harder to find these days
0
POPSMicrobicides could lead to tougher HIV
An estimated 33 million people have HIV. 66% in Africa. More than 61% of Africans with HIV are women who have been infected by their partners. They have found tougher HIV is not as likely to be transmitted. Microbicides work with consistent application, and in conjunction with anti HIV medication, which may not be taken. Reminds me of how Penicillin was once considered to be the the cure for many known diseases. It wasn't long before bacteria developed that were resistant, and the next generation of antibiotics needed to be developed. Now we have the top of the line Methycillin, and MRSA-Methycyllin resistant Staphylococcus Aureas -Golden Staph, and we're reaching the end of this line.. We tried to beat nature, and nature caught us and beat us back. As penicillin was a natural by product of a microorganism, it stands to reason that as many other species have natural antibiotics and defense mechanisms, we can find the next generation of antibiotics by following natures lead.
1
POPSThe NYT On Avastin The New York Times has a long takeout in the Sunday paper on the conundrum raised by Genentech's Avastin: How much can society afford to pay for a treatment that, while beneficial, only extends median survival by a little bit? An interesting bit of new information comes out in between the analysis and stirring narrative. Genentech and Roche have spent more than $2.25 billion to develop Avastin. That's an interesting figure -- about as much as the drug made in sales last year. It does serve as a reminder that it is drug companies, not the government, that really pay for developing new medicines. What makes the Avastin conundrum difficult is that it is one of the biggest sellers introduced in recent memory. If Avastin's not worth the money, there are some hard questions that need to be asked about the incentives currently at work in drug development.
20
POPS Viagra for the brain? It’s not an amphetamine or stimulant, the article explained: it doesn’t make you high, or wired. It seems to work by restricting the parts of your brain that make you sluggish or sleepy. No significant negative effects have been discovered. Now students are using it in the run-up to exams as a “smart drug” – a steroid for the mind.
20
POPSMoral Philosopher Questions Memory Manipulation Hurley says while the real threat of developing PTSD might be a good enough reason to use beta-blockers as a preventative measure, she also wants policy makers to consider the ramifications of what such a treatment may mean to a person’s moral well-being. “Beta-blockers do not cause amnesia. Rather they make memories less vivid, detailed and arousing,” explains Hurley, who specializes in bioethics. “They lessen the emotional impact when someone is recalling upsetting events.”
1
Pops
Newest Clips
Latest Comments
Most Pops
Print
Save
Turn on live update